High-Quality Registry and Follow-Up Study of Biopsy-Confirmed IgA Nephropathy Patients in China

What this Trial Is About

Researchers are creating a registry and database for patients in China diagnosed with biopsy-confirmed primary IgA nephropathy IgAN. The study aims to collect detailed patient information and follow these patients annually to assess important health outcomes such as overall mortality, cardiovascular death, and kidney function decline leading to serious kidney failure. Participants include patients with biopsy-proven primary IgAN. The study involves registering patients from multiple hospitals and collecting baseline data including demographics, clinical status, lab tests, complications, and medication use. Follow-up visits occur yearly to update this information and record clinical events like hospitalizations, deaths, and kidney failure requiring dialysis or transplantation. Participants will be followed for up to 10 years, with annual assessments of their health status and kidney function. The research team will analyze the database to compare rates of death and kidney disease progression among IgAN patients. This observational study does not involve experimental treatments and focuses on detailed long-term data collection to better understand disease outcomes.

IgA Nephropathy Registration Initiative of High Quality (INSIGHT)